Side Effects of paclitaxel (with albumin) injection: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of paclitaxel (with albumin) injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of paclitaxel (with albumin) injection: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of paclitaxel (with albumin) injection: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Several studies have shown that paclitaxel (albumin-bound) injection has fewer side effects and greater antitumor efficacy compared to traditional formulations. 10 , 7 , 8 These studies reported that paclitaxel (albumin-bound) injection has better tumor penetration and reduced side effects. 9 , 3

Reasons for Side Effects

The side effects of paclitaxel (albumin-bound) injection vary depending on the properties of the drug and the method of administration. For example, nanoparticle formulations are said to have fewer side effects than conventional formulations. 7 Also, the side effects may differ depending on the method of administration. 6

Common Side Effects

Sensory Neuropathy

The most common side effect of paclitaxel (albumin-bound) injection is sensory neuropathy. 8 Sensory neuropathy causes numbness and pain in the hands and feet. 8

Stomatitis

Stomatitis is a side effect in which the mouth becomes inflamed. 8 Stomatitis causes mouth sores and pain. 8

Skin Toxicity

Skin toxicity is a side effect that causes skin inflammation. 6 Skin toxicity can cause rashes and itching. 6

Ocular Toxicity

Ocular toxicity is a side effect that causes eye inflammation. 1 Ocular toxicity can cause vision loss and visual disturbances. 1

Countermeasures for Side Effects

Sensory Neuropathy

Sensory neuropathy can sometimes be alleviated by reducing the dosage of the drug. 8 In addition, taking vitamin B12 and other nutrients may reduce the symptoms of sensory neuropathy. 8

Stomatitis

Stomatitis can be alleviated by using mouthwashes and oral care products. 8 In addition, dietary therapy may reduce the symptoms of stomatitis. 8

Skin Toxicity

Skin toxicity can sometimes be alleviated by using steroid ointments and antihistamines. 6

Ocular Toxicity

Ocular toxicity can sometimes be alleviated by using steroid eye drops. 1

Comparison of Studies

Commonalities of Studies

These studies have shown that paclitaxel (albumin-bound) injection has fewer side effects and greater antitumor efficacy compared to traditional formulations. 10 , 7 , 8

Differences in Studies

Studies vary in the types and severity of side effects associated with paclitaxel (albumin-bound) injection. 6 , 1 These differences may be due to differences in the formulation and method of administration of the drug. 6 , 1

Precautions for Real-Life Applications

Paclitaxel (albumin-bound) injection has been shown to have fewer side effects and greater antitumor efficacy compared to traditional formulations. 10 , 7 , 8 However, side effects are not completely absent. 6 , 1 When using paclitaxel (albumin-bound) injection, it is important to consult with your doctor and understand the risks and benefits of treatment before receiving treatment. 6 , 1

Current Research Limitations

Research on paclitaxel (albumin-bound) injection is still in its early stages, and information on side effects is limited. 6 , 1 Further research is needed. 6 , 1

Future Research Directions

It is necessary to investigate the side effects of paclitaxel (albumin-bound) injection in more detail. 6 , 1 It is also necessary to develop new methods to reduce side effects. 6 , 1

Conclusion

Paclitaxel (albumin-bound) injection has been shown to have fewer side effects and greater antitumor efficacy compared to traditional formulations. 10 , 7 , 8 However, side effects are not completely absent. 6 , 1 When using paclitaxel (albumin-bound) injection, it is important to consult with your doctor and understand the risks and benefits of treatment before receiving treatment. 6 , 1

Literature analysis of 12 papers
Positive Content
9
Neutral Content
0
Negative Content
3
Article Type
0
0
0
2
11
1.

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer.

Author: YamaneHiroaki, ItagakiTomoko, KajitaniKeiko, KouraYuji, KawabuchiYoshiharu, OharaMasahiro

None mentioned
Cystoid macular edema

This case report describes a 49-year-old woman who developed cystoid macular edema (CME) while receiving chemotherapy with Nab-PTX and atezolizumab. The CME resolved after discontinuation of chemotherapy, highlighting the importance of recognizing and managing ophthalmologic side effects during cancer treatment.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

3.

Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment.

Author: LiLi, QianYujin, SunLuyao, HanFelicity Y, ZhangRun, WangPeng-Yuan, XuZhi Ping

Inhibited tumor growth

This study developed a new nanomedicine system to simultaneously deliver two anti-tumor drugs, 5FU and ABX, for colorectal cancer treatment. The results suggest that this new approach may be a promising strategy for treating colorectal cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.

Author: O'ReillyEileen M, RoachJames, MillerPaul, YuKenneth H, TjanCatherine, RosanoMolly, KrauseSilva, AveryWilliam, WolfJulie, FlahertyKeith, NixDarrell, RyanDavid P

Anticoagulant effect
Skin toxicity

This study evaluated the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma. Although safety was documented, dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity, and a low-level anticoagulant effect.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Advances of paclitaxel formulations based on nanosystem delivery technology.

Author: LuoC, WangY, ChenQ, HanX, LiuX, SunJ, HeZ

Cancer treatment
Reduced paclitaxel toxicity

This paper provides an overview of recent advances in paclitaxel formulations based on nanosystems. These nanoformulations address paclitaxel's poor aqueous solubility and reduce its toxicities while enhancing its antitumor efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Author: SugaharaKazuki N, TeesaluTambet, KarmaliPriya Prakash, KotamrajuVenkata Ramana, AgemyLilach, GreenwaldDaniel R, RuoslahtiErkki

Enhanced efficacy
Improved drug penetration
Reduced side effects

This study explores the use of a tumor-penetrating peptide, iRGD, to enhance the delivery of anticancer drugs to tumors. iRGD improved the therapeutic index of various drugs, suggesting it may be a valuable tool for improving cancer therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

11.

Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.

Author: LeschHanna P, PikkarainenJere T, KaikkonenMinna U, TaavitsainenMiia, SamaranayakeHaritha, Lehtolainen-DalkilicPauliina, VuorioTaina, MäättäAnn-Marie, WirthThomas, AirenneKari J, Ylä-HerttualaSeppo

Cancer treatment
Repeated administration
Antibody production
Lentiviral side effects

A lentiviral vector expressing a fusion protein of avidin and the endocytotic part of the low-density lipoprotein receptor was shown to be safe and effective in targeting cytotoxic compounds to cancer cells.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.